Searchable abstracts of presentations at key conferences in endocrinology

ea0028p54 | Clinical practice/governance and case reports | SFEBES2012

Survey of hypercalcaemia and audit of further management with focus on primary hyperparathyroidism

Raghavan R P , Gkastaris K , Chortis V , Woltersdorf W W , Bradley K J

Background: Hypercalcaemia is independently associated with increased cardiovascular morbidity/mortality. It is a poor prognostic marker in malignancy. Best practice dictates further investigation of any high calcium values. Recognition of primary hyperparathyroidism (PHPT) is important for long term follow-up and management.Aims: Survey of causes of hypercalcaemia in adults (>18 years) from samples sent to one hospital lab over 1 year with particula...

ea0029p782 | Endocrine tumours and neoplasia | ICEECE2012

Urinary steroid profiling demonstrates induction of CYP3A4 and inhibition of 5alpha-reductase by mitotane treatment for adrenocortical carcinoma

Taylor A. , Chortis V. , Schneider P. , Tomlinson J. , Hughes B. , Smith D. , Libe R. , Allolio B. , Bertagna X. , Bertherat J. , Beuschlein F. , Fassnacht M. , Mannelli M. , Mantero F. , Opocher G. , Porfiri E. , Quinkler M. , Terzolo M. , Shackelton C. , Stewart P. , Hanher S. , Arlt W.

Mitotane (o,p’DDD) is commonly used for the treatment of adrenocortical carcinoma (ACC), both for advanced disease and in the adjuvant setting. Mitotane induces adrenal insufficiency but specific effects on steroidogenic enzymes are unknown.We investigated 24-h urinary steroid metabolite excretion in ACC patients on adjuvant mitotane (AD) or mitotane for metastatic disease (MET). We compared samples collected before mitotane treatment (BEFORE; MET <...